Concurrent Investment Advisors LLC Buys 973 Shares of Sanofi (NASDAQ:SNY)

Concurrent Investment Advisors LLC grew its stake in shares of Sanofi (NASDAQ:SNY) by 2.6% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 37,946 shares of the company’s stock after acquiring an additional 973 shares during the period. Concurrent Investment Advisors LLC’s holdings in Sanofi were worth $1,830,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Abel Hall LLC raised its stake in shares of Sanofi by 1.8% during the fourth quarter. Abel Hall LLC now owns 10,990 shares of the company’s stock valued at $530,000 after acquiring an additional 194 shares in the last quarter. PDS Planning Inc raised its stake in shares of Sanofi by 3.1% during the third quarter. PDS Planning Inc now owns 6,643 shares of the company’s stock valued at $383,000 after acquiring an additional 200 shares in the last quarter. Eagle Ridge Investment Management raised its stake in shares of Sanofi by 3.8% during the third quarter. Eagle Ridge Investment Management now owns 5,571 shares of the company’s stock valued at $321,000 after acquiring an additional 203 shares in the last quarter. Financial Advocates Investment Management raised its stake in shares of Sanofi by 3.4% during the third quarter. Financial Advocates Investment Management now owns 6,327 shares of the company’s stock valued at $365,000 after acquiring an additional 206 shares in the last quarter. Finally, Angeles Investment Advisors LLC raised its stake in shares of Sanofi by 1.9% during the third quarter. Angeles Investment Advisors LLC now owns 11,323 shares of the company’s stock valued at $653,000 after acquiring an additional 210 shares in the last quarter. Institutional investors own 14.04% of the company’s stock.

Sanofi Stock Performance

Shares of SNY stock opened at $54.46 on Friday. The firm has a market cap of $138.21 billion, a price-to-earnings ratio of 21.87, a PEG ratio of 1.00 and a beta of 0.57. The company’s 50 day moving average is $50.95 and its 200 day moving average is $52.52. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. Sanofi has a 52-week low of $45.22 and a 52-week high of $58.97.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. On average, sell-side analysts anticipate that Sanofi will post 4.36 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on SNY shares. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. StockNews.com lowered shares of Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Finally, Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. Two equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $60.00.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.